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A BS TR AC T
Background
Hepatocellular carcinoma is the third leading cause of cancer-related deaths world-
wide. In the heterogeneous group of hepatocellular carcinomas, those with charac-
teristics of embryonic stem-cell and progenitor-cell gene expression are associated 
with the worst prognosis. The oncofetal gene SALL4, a marker of a subtype of hepa-
tocellular carcinoma with progenitor-like features, is associated with a poor prog-
nosis and is a potential target for treatment.
Methods
We screened specimens obtained from patients with primary hepatocellular carci-
noma for the expression of SALL4 and carried out a clinicopathological analysis. 
Loss-of-function studies were then performed to evaluate the role of SALL4 in he-
patocarcinogenesis and its potential as a molecular target for therapy. To assess the 
therapeutic effects of a peptide that targets SALL4, we used in vitro functional and 
in vivo xenograft assays.
Results
SALL4 is an oncofetal protein that is expressed in the human fetal liver and silenced 
in the adult liver, but it is reexpressed in a subgroup of patients who have hepatocel-
lular carcinoma and an unfavorable prognosis. Gene-expression analysis showed 
the enrichment of progenitor-like gene signatures with overexpression of prolifera-
tive and metastatic genes in SALL4-positive hepatocellular carcinomas. Loss-of-
function studies confirmed the critical role of SALL4 in cell survival and tumorige-
nicity. Blocking SALL4–corepressor interactions released suppression of PTEN (the 
phosphatase and tensin homologue protein) and inhibited tumor formation in xe-
nograft models in vivo.
Conclusions
SALL4 is a marker for a progenitor subclass of hepatocellular carcinoma with an 
aggressive phenotype. The absence of SALL4 expression in the healthy adult liver 
enhances the potential of SALL4 as a treatment target in hepatocellular carcinoma. 
(Funded by the Singapore National Medical Research Council and others.)
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Hepatocellular carcinoma is the third leading cause of cancer-related deaths globally. Although the epidemio-
logic risk factors for hepatocellular carcinoma 
are well known,1 the molecular mechanisms un-
derlying hepatocarcinogenesis are not well char-
acterized. Elucidation of these mechanisms may 
allow identification of new candidates for thera-
peutic targeting. Although surgery, liver transplan-
tation, and radiologic intervention may be viable 
options for patients with early-stage disease, the 
prognosis associated with advanced-stage hepa-
tocellular carcinoma remains bleak.2 Combination 
chemotherapy has not improved overall survival but 
has nonetheless been in wide use for many years 
because of its possible role in palliation. The need 
to understand the molecular pathogenesis of he-
patocellular carcinoma and develop more effec-
tive targeted therapies remains urgent.
The human homologue of the Drosophila spalt 
homeotic gene, SALL4, encodes a C2H2 zinc-finger 
transcription factor.3 It is one of the key factors 
for maintenance of pluripotency and self-renew-
al of embryonic stem cells.4-6 In the murine liver, 
Sall4 expression diminishes gradually during de-
velopment and is silenced by adulthood; this sug-
gests a role for Sall4 during early-to-middle de-
velopment of the fetal liver.7 SALL4 is an oncogene 
that was first described in leukemia. SALL4 was 
found to be constitutively expressed in human 
acute myeloid leukemia, and acute myeloid leu-
kemia developed in SALL4B-transgenic mice.8 Sub-
sequently, SALL4 expression has been reported in 
various types of cancers9,10 and is proposed to have 
diagnostic value in several of them.11-13
The progenitor-like subtype of hepatocellular 
carcinoma is known to be associated with a poor 
prognosis.14 The expression of Sall4 in murine fetal 
liver but not in adult liver led us to hypothesize 
that SALL4 might be an important marker for the 
progenitor-like subtype of hepatocellular carcino-
ma. We also hypothesized that SALL4 would con-
tribute to the development and persistence of 
hepatocellular carcinoma when it was expressed 
in hepatocytes in adults.
Me thods
Patients and Samples
We obtained specimens of hepatocellular carci-
noma from patients at the National University 
Hospital in Singapore (hereafter referred to as 
the Singapore specimens) to construct hepatocellu-
lar-carcinoma tissue microarrays. We also analyzed 
a second batch of specimens obtained from pa-
tients at the Queen Mary Hospital in Hong Kong 
(hereafter referred to as the Hong Kong specimens). 
The patients received various treatments and were 
not participants in any clinical trials evaluating 
treatment approaches. The institutional review 
board of the National University of Singapore ap-
proved the study, and patients provided written 
informed consent for the use of all surgically re-
moved tissue specimens used in this study.
Study Conduct
The study had no commercial sponsors. The au-
thors vouch for the accuracy and completeness of 
the data and analysis. No one who is not listed as 
an author contributed to the manuscript. Four of 
the authors hold a patent application for intel-
lectual property derived from this study.
Statistical Analysis
All experiments were performed in triplicate un-
less otherwise stated. Statistical analyses were 
performed with the use of SPSS software, ver-
sions 15.0 and 16.0 (SPSS). To examine the as-
sociation between levels of SALL4 expression 
and clinicopathological characteristics, Fisher’s 
exact test was used for analysis of the Singapore 
specimens of primary hepatocellular carcinomas 
and the chi-square test was used for analysis of 
the Hong Kong specimens. In the Hong Kong 
specimens, levels of SALL4 expression were di-
vided into two groups. The group with a high 
level of SALL4 expression (high-SALL4 group) had 
SALL4 expression intensity that was equal to or 
exceeded the median level of expression detected 
on microarray analysis, whereas the group with a 
low level of SALL4 expression (low-SALL4 group) 
had SALL4 expression intensity that was lower 
than the median level of expression. Univariate 
analyses of cumulative overall survival and tu-
mor recurrence were performed with the use of a 
Cox proportional-hazards regression model in the 
Singapore cohort and with the use of the Kap-
lan–Meier method followed by the log-rank test 
in the Hong Kong cohort. Factors with prognos-
tic significance were included in the subsequent 
multivariate analyses with the use of the Cox 
proportional-hazards regression model in both 
cohorts. For statistical analysis of the Singapore 
specimens of primary hepatocellular carcinomas, 
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79 of the 179 specimens for which full clinico-
pathological data were available were analyzed. 
The correlation significance was determined by 
means of Spearman and Pearson correlation anal-
yses. The chi-square test and Student’s t-test were 
used for comparisons between the high-SALL4 
and low-SALL4 groups. A P value of 0.05 or less 
was considered to indicate statistical significance.
R esult s
SALL4 Expression in Hepatocellular Carcinoma
To test our hypothesis that SALL4 is reexpressed 
in a subtype of hepatocellular carcinoma, we exam-
ined the expression of SALL4 in liver specimens 
from patients with and those without hepatocel-
lular carcinomas. With the use of immunohisto-
chemical analysis, we detected SALL4 expression 
in fetal liver specimens but not in adult liver 
specimens (Fig. 1A).
We then investigated the level of expression 
of SALL4 in patients with hepatocellular carci-
noma. We constructed a panel of tissue microar-
rays consisting of 179 surgically resected speci-
mens of primary hepatocellular carcinomas and 
matched, archived, non-neoplastic liver specimens 
obtained from the National University Hospital 
in Singapore. The patients in the Singapore co-
hort were approximately 56 years of age, 81% 
were men, and 87.3% had grade I or II tumors. 
Detailed demographic and clinicopathological 
characteristics of these patients are described in 
Table S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org. 
With the use of immunohistochemical analysis, 
we observed differential expression of SALL4 in 
matched tissue specimens, with more SALL4-
expressing cells in the specimens with hepato-
cellular carcinoma than in the matched non-neo-
plastic specimens (P<0.001) (Fig. 1B). Data from 
the immunohistochemical analysis showed SALL4 
positivity in 55.6% (95 of 171) of the hepatocel-
lular carcinoma specimens analyzed, albeit at vari-
ous levels of expression (Table S2 in the Supple-
mentary Appendix).
We further confirmed SALL4 up-regulation by 
means of gene-expression microarray analysis in 
various independent groups of specimens of pri-
mary hepatocellular carcinoma. In a group of 
228 matched neoplastic and non-neoplastic liver 
specimens obtained from patients in Hong Kong, 
we detected differential SALL4 expression (P<0.001) 
(Fig. 1C), which was similar to the pattern of ex-
pression observed in the Singapore specimens. 
Table S3 in the Supplementary Appendix lists the 
demographic and clinicopathological character-
istics of the patients with hepatocellular carcino-
ma in the Hong Kong cohort. Furthermore, we 
pooled various global gene-expression data from 
public databases and observed differential SALL4 
expression in the hepatocellular-carcinoma and 
non-neoplastic liver-tissue specimens (P = 0.003) 
(Fig. 1D). From these sizable independent groups 
of adult liver specimens, we confirmed that SALL4 
was up-regulated in the subgroup of specimens 
with hepatocellular carcinoma but remained si-
lenced in the matched non-neoplastic specimens.
Analysis of endogenous SALL4 expression 
across a panel of 10 human hepatocellular carci-
noma cell lines by means of a quantitative 
polymerase-chain-reaction assay showed the ex-
pression of SALL4 at various levels, reflecting the 
expression pattern observed in the hepatocellu-
lar carcinoma tissue specimens described above 
(Fig. 1E). Moreover, SALL4 expression was not 
detected in the two immortalized, nontransformed 
liver-cell lines, THLE-2 and THLE-3. These data 
Figure 1 (facing page). SALL4 Expressed in Human 
Fetal Liver, Silenced in Adult Liver, and Reactivated  
in a Subtype of Hepatocellular Carcinoma.
Panel A shows immunohistochemical staining of for-
malin-fixed, paraffin-embedded human fetal liver and 
human adult liver. SALL4 expression is indicated by 
brown staining. Scale bars indicate 100 μm. Panel B 
shows immunohistochemical staining of a hepatocel-
lular carcinoma specimen and the matched non-neo-
plastic liver specimen on tissue microarray analysis. 
SALL4 expression was detected in the hepatocellular 
carcinoma tissue and localized in the nucleus, as indi-
cated by the brown staining. Scale bars indicate 100 μm. 
Panel C shows differential SALL4 expression in 228 
matched specimens of primary hepatocellular carci-
noma and non-neoplastic liver tissue from the Hong 
Kong cohort, as determined by means of microarray 
analysis. Panel D shows microarray SALL4 expression 
in primary hepatocellular carcinoma and non-neoplas-
tic liver tissue on the basis of pooled data from public 
databases. Panel E shows the results of quantitative 
reverse-transcriptase–polymerase-chain-reaction analy-
sis of SALL4A (left) and SALL4B (right) expression in 
10 human hepatocellular-carcinoma cell lines and two 
immortalized nontransformed hepatocyte cell lines, 
THLE-2 and THLE-3. All values were normalized to 
ACTB and plotted relative to the expression of the 
THLE-2 cell line.
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suggest that these cell lines are appropriate mod-
els for further testing of our hypothesis and 
confirm our finding that SALL4 is reexpressed in 
a subgroup of hepatocellular carcinomas.
In summary, the results obtained from a 
number of different assays and groups of clini-
cal specimens showed that SALL4 was ex-
pressed in fetal liver tissue, silenced in normal 
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adult liver tissue, and reexpressed in many of 
the tissue specimens from adults with hepato-
cellular carcinoma (Fig. S2 in the Supplemen-
tary Appendix).
SALL4 as a Prognostic Factor  
for Hepatocellular Carcinoma
To analyze the clinical relevance of SALL4 reacti-
vation in hepatocellular carcinoma, we carried 
out a clinicopathological analysis of the Singa-
pore and Hong Kong specimens of primary hepa-
tocellular carcinoma. This analysis showed that 
patients with a high level of SALL4 expression 
had a worse prognosis than patients with a low 
level of SALL4 expression. A univariate analysis 
of survival among patients in the Singapore co-
hort showed that the absence of SALL4 protein (an 
immunohistochemical score of 0 on a scale of 0 to 
4, with higher scores indicating a greater propor-
tion of positive cells [see the Supplementary 
Methods section in the Supplementary Appen-
dix]), conferred a significant survival advantage 
(P = 0.02) (Fig. 2A). Similarly, SALL4 expression 
was associated with poor survival among the pa-
tients in the Hong Kong cohort (P = 0.002) (Fig. 2B). 
Our univariate analysis also showed that SALL4 
was associated with disease recurrence in both 
the Singapore cohort (Table S4 in the Supplemen-
tary Appendix) and the Hong Kong cohort (Table 
S5 in the Supplementary Appendix).
In addition, our association studies confirmed 
that SALL4 expression status was not associated 
with baseline liver function or the tumor–node–
metastasis and Barcelona Clinic Liver Cancer stag-
es in either the Singapore cohort (Table S1 in the 
Supplementary Appendix) or the Hong Kong 
cohort (Table S3 in the Supplementary Appendix). 
Moreover, SALL4 expression status in the Singa-
pore cohort did not differ significantly accord-
ing to whether the patients received or did not 
receive preoperative treatment. In a multivariate 
Cox regression model, SALL4 was an independent 
prognostic factor for overall survival (hazard ratio 
for death, 2.87; 95% confidence interval [CI], 
1.09 to 7.52; P = 0.03) in the Singapore cohort 
(Table S6 in the Supplementary Appendix) and 
an independent predictor of both overall survival 
(hazard ratio for death, 1.52; 95% CI, 1.00 to 2.32; 
P = 0.05) and early recurrence (hazard ratio, 1.67; 
95% CI, 1.11 to 2.51; P = 0.01) in the Hong Kong 
cohort (Table S7 in the Supplementary Appendix), 
after adjustment for other clinicopathological 
features that have conventionally been accepted 
as having prognostic value in hepatocellular car-
cinoma.
Gene-profiling studies suggest that patients 
with cancers that have embryonic stem-cell or he-
patic progenitor cell–like gene-expression signa-
tures have a poor prognosis.14-16 To investigate 
whether SALL4-positive hepatocellular carcino-
mas share a gene-expression pattern with fetal 
hepatoblasts, we extracted global gene-expression 
data on hepatocytes, fetal liver tissue, and hepa-
tocellular carcinomas (all from humans) from 
the Gene Expression Omnibus database for hier-
archical cluster analysis. Our analysis showed 
that high-SALL4 hepatocellular carcinomas clus-
tered tightly with fetal livers, whereas the low-
SALL4 hepatocellular carcinomas clustered with 
normal hepatocytes (Fig. 2C). These findings sug-
gest that hepatocellular carcinomas that express 
SALL4 have a gene-expression pattern that is simi-
lar to the pattern in hepatic progenitor cells and 
thus are poorly differentiated, aggressive, and 
associated with a poor prognosis.
We next examined the importance of SALL4 
in hepatocellular carcinoma by performing loss-of-
function studies. Knocking down SALL4 by means 
of short hairpin RNA (shRNA) caused a decrease 
in cell viability, an increase in apoptosis, and a 
decrease in tumorigenicity of hepatocellular car-
cinoma cells (Fig. S1 in the Supplementary Ap-
pendix). To investigate whether loss of SALL4 in 
hepatocellular carcinoma cells reverses the ag-
gressive progenitor-like phenotype, we carried 
out microarray analysis of gene-expression pro-
files of SNU-398 cells treated with control scram-
bled shRNA (Scr shRNA 1) or SALL4-specific 
shRNA (shSALL4 1) and then performed hierar-
chical clustering of these profiles along with those 
derived from normal human hepatocytes and fe-
tal liver tissues. As expected, SNU-398 cells treated 
with scrambled shRNA 1 clustered closely with 
human fetal liver tissue, since both express high 
levels of SALL4. SALL4–knocked down SNU-398 
cells clustered with human hepatocytes; this sug-
gested that down-regulation of SALL4 can render 
hepatocellular carcinoma more hepatocyte-like 
with respect to gene expression (Fig. 2D).
To correlate the subgroup of SALL4-positive 
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Figure 2. Poor Prognosis Predicted by SALL4 Expression in Hepatocellular Carcinoma.
In Panel A, Kaplan–Meier curves show a lower rate of overall survival with SALL4-postive hepatocellular carcinomas 
than with SALL4-negative hepatocellular carcinomas in the Singapore cohort. In Panel B, Kaplan–Meier curves show 
a lower probability of overall survival with high-SALL4 hepatocellular carcinomas in the Hong Kong cohort. In Panel 
C, the dendrogram and heat map show the hierarchical cluster analysis of gene-expression data from human speci-
mens of primary hepatocytes, fetal liver tissue, and hepatocellular carcinoma; gene-expression profiles were ob-
tained from public databases. Columns represent individual samples, and rows represent individual genes. Each cell 
in the matrix represents the expression level of a gene in an individual sample. The scale bar indicates the level of 
expression; red indicates a high level of expression, and green a low level of expression. In Panel D, the dendrogram 
and heat map show the hierarchical cluster analysis of gene-expression data from human specimens of primary he-
patocytes, fetal liver tissue, and SNU-398 cells transduced with scrambled short hairpin RNA 1 or SALL4-specific 
shRNA (shSALL4 1).
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hepatocellular carcinomas with oncogenic path-
ways in primary hepatocellular carcinoma speci-
mens, we carried out gene-set enrichment analysis 
to investigate the enrichment of pathways that 
have prognostic value in SALL4-high and SALL4-
low hepatocellular carcinomas. We found that 
genes that were up-regulated in hepatocellular 
carcinoma associated with poor survival, genes 
in an embryonic stem-cell signature, and genes 
that were up-regulated in metastasis, hepatoblas-
toma, and a proliferation subclass of hepatocel-
lular carcinoma17 were significantly enriched in 
the high-SALL4 hepatocellular-carcinoma subgroup 
(Fig. 3A through 3E). Taken together, these data 
suggest that the expression of oncofetal protein 
SALL4 can be used as a molecular marker to 
identify an aggressive progenitor cell–like sub-
type of hepatocellular carcinoma and that SALL4 
expression has prognostic value for patients with 
hepatocellular carcinoma.
Targeting SALL4 by a Novel Peptide
Our loss-of-function studies suggested that SALL4 
is a potential therapeutic target for hepatocellu-
lar carcinoma and that down-regulation of SALL4 
might reverse the aggressive phenotype of hepa-
tocellular carcinomas. We next sought to develop 
targeted therapy to antagonize the oncogenic 
role of SALL4. It is known that SALL4 functions 
as a transcription repressor by recruiting a his-
tone deacetylase (HDAC)–containing nucleosome 
remodeling and HDAC (NuRD) complex, and 
that the tumor suppressor PTEN (phosphatase 
and tensin homologue) is among the target genes 
repressed by SALL4.19 Our SALL4 loss-of-func-
tion microarray data provided direct evidence 
that in hepatocellular carcinoma, the PTEN–AKT 
pathway is involved in SALL4-induced hepatocar-
cinogenesis, since the class I phosphatidylinosi-
tol 3–kinase (PI3K) signaling events mediated by 
AKT were significantly affected by SALL4 down-
regulation (P = 0.02).
We recently described a SALL4 12-AA peptide 
as a competitive inhibitor that blocks the inter-
action between SALL4 and NuRD and as a result 
blocks the NuRD-mediated SALL4-repression 
function.20 We tested whether this 12-AA SALL4 
peptide was effective in targeting the SALL4–
PTEN–AKT pathway and resulted in decreased 
viability of hepatocellular carcinoma cells. When 
5 μM or 20 μM of nonmutant SALL4 peptide was 
added to SNU-398 cells, the number of viable 
cells was reduced, as compared with SNU-398 cells 
treated with control mutant peptide and scram-
bled peptide. Trichostatin A, a general HDAC 
inhibitor, was used as a positive control drug.21,22 
When the PTEN inhibitor SF1670 was added to 
the cells treated with SALL4 peptide, it rescued 
the phenotype, as evidenced by the maintenance 
of cell viability (Fig. 4A). These results suggest 
that PTEN plays an important role in the SALL4 
peptide–induced loss of tumor-cell viability in 
hepatocellular carcinoma. In contrast, SALL4 
peptide had no effect on SNU-387 cells with 
undetectable endogenous SALL4 expression (Fig. 
4B). This finding suggests that SALL4 peptide is 
a specific agent inhibiting SALL4-overexpressing 
hepatocellular carcinoma cells, with minimal 
toxic effects on SALL4-negative cells, as com-
pared with the HDAC inhibitor trichostatin A.
To confirm the involvement of the tumor sup-
pressor PTEN in the SALL4 peptide–induced re-
duction of hepatocellular carcinoma cell viability, 
we analyzed PTEN expression by means of West-
ern blotting. SALL4 peptide treatment induced 
an extensive increase in levels of PTEN protein 
in SNU-398 cells (Fig. 4C). In contrast, SALL4 
peptide had a negligible effect on PTEN expres-
sion in SNU-387 cells (Fig. 4D). We next exam-
Figure 3 (facing page). Enriched Gene Signatures Asso-
ciated with a Poor Prognosis in High-SALL4 Hepatocel-
lular Carcinoma.
Enrichment of genes associated with poor survival 
(Panel A), embryonic stem cells (Panel B), metastasis 
(Panel C), hepatoblastoma (Panel D), and a prolifera-
tion subclass of hepatocellular carcinoma was de-
scribed by Chiang et al.17 (Panel E) in high-SALL4 he-
patocellular carcinoma. The heat maps show the 
enrichment of genes implicated in the gene sets. Col-
umns represent individual samples, and rows repre-
sent each gene. Each cell in the matrix represents the 
expression level of a gene in an individual sample. Red 
indicates a high level of expression, and green a low 
level of expression. NES denotes normalized enrich-
ment score in gene-set enrichment analysis. An NES 
score of more than 1 indicates enrichment of the gene 
set in high-SALL4 hepatocellular carcinoma. The ranked 
list metric was generated by calculating the signal-to-
noise ratio,18 which is based on the difference of means 
scaled according to the standard deviation. The larger 
the signal-to-noise ratio, the more distinct the gene ex-
pression is in each phenotype and the more the gene 
acts as a “class marker.” The Broad Institute Gene Set 
Enrichment Analysis website (www.broad.mit.edu/
gsea) provides detailed information about the com-
putational method.
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Figure 4. Specific Targeting of SALL4 by SALL4 Peptide in Hepatocellular Carcinoma Cells with High SALL4 Expression.
A 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium cell-viability assay shows 
the effects of SALL4 peptide on SNU-398 cells with high endogenous SALL4 expression (Panel A) and SNU-387 cells with 
undetectable SALL4 expression (Panel B). Cell viability was determined 72 hours after peptide treatments. Absorbance at 
490 nm was directly correlated with cell viability. Nonmutant functional SALL4 peptide, mutant nonfunctional peptide, 
trichostatin A (TSA), scrambled control peptide, and nonmutant peptide plus PTEN (phosphatase and tensin homologue) 
inhibitor were added to the cells at the indicated concentration. The PTEN inhibitor concentration was 400 nM (Panels A 
through D). In Panels A and B, treatment 1 was a no-treatment control, treatment 2 was treatment of cells with 5 μM of 
peptides or 50 nM of TSA, and treatment 3 was treatment of cells with 20 μM of peptides or 100 nM of TSA. Western 
blot analyses show the effects of peptides on PTEN, AKT, and phosphorylated AKT (pAKT) expression on SNU-398 cells 
(Panel C) and SNU-387 cells (Panel D) 72 hours after peptide treatments; α-tubulin was analyzed as a loading control. 
Twenty μM of nonmutant or scrambled peptide or 100 nM of TSA was used. The PTEN inhibitor concentration was 400 nM. 
Panel E shows nonobese diabetic mice with severe combined immunodeficiency that underwent transplantation with 3 mil-
lion SNU-398 cells at the left flank and were treated intraperitoneally for 5 consecutive days with 56 mg of TAT-mutant 
peptide per kilogram of body weight or 60 mg of nonmutant peptide per kilogram (top panel). The dissected subcuta-
neous tumors are shown below. Panel F shows the mean weight of tumors dissected at day 18 after transplantation 
and treatment in five mice that received TAT fusion peptides intraperitoneally. T bars indicate standard deviations.
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ined whether the increase in PTEN expression 
had an effect on PI3K signaling. PTEN functions 
as a phosphatase to dephosphorylate AKT. West-
ern blot analysis showed a marked reduction of 
phosphorylated AKT protein levels with SALL4 
peptide treatment in SNU-398 cells (Fig. 4C), but 
not in low-SALL4 SNU-387 cells (Fig. 4D); this 
suggests that the increase in the level of PTEN 
expression had a functional role in blocking the 
PI3K survival signaling by dephosphorylating AKT. 
Furthermore, this effect could be rescued by the 
PTEN inhibitor, which is consistent with the role 
of SALL4 in regulating this pathway.
To further test the therapeutic effect of this 
peptide for in vivo treatment, we conjugated mu-
tant and nonmutant peptides with the transacti-
vator of transcription (TAT) protein transduction 
domain and administered the peptides intraperi-
toneally in nonobese diabetic mice with severe 
combined immunodeficiency, in which SNU-398 
cells had been transplanted subcutaneously. TAT 
fusion nonmutant peptides reduced the tumori-
genicity of SNU-398 hepatocellular carcinoma cells 
(Fig. 4E). The tumor loads at 18 days after treat-
ment in mice that received TAT-nonmutant pep-
tides were significantly smaller than tumor 
loads in mice that received TAT–mutant peptides 
(Fig. 4F). These experiments confirm that the 
SALL4 peptide had biologic activity both in vitro 
and in vivo in a xenotransplant model.
Our in vitro and murine data suggest that the 
SALL4 peptide is a potential targeted therapy for 
a subgroup of hepatocellular carcinomas, since it 
effectively and specifically reduced viable SALL4-
positive hepatocellular carcinoma cells.
Discussion
Hepatocellular carcinoma is one of the deadliest 
cancers, with a ratio of mortality to incidence of 
almost 1.1 Our study shows the unique expres-
sion pattern of the stem-cell factor SALL4 in hu-
man livers at various stages — activated in fetal 
liver tissue, silenced in adult liver tissue, and re-
expressed as an oncofetal protein in hepatocel-
lular carcinoma.
Identification of reliable biomarkers that can 
be used to predict patient outcomes ensures more 
effective clinical management, and we propose 
that SALL4 is such a biomarker in hepatocellular 
carcinoma. The reexpression of SALL4 in hepa-
tocellular carcinoma is clinically significant, since 
patients with the subtype that overexpresses SALL4 
have enriched hepatic progenitor cell–like gene 
signatures and tend to have a poor prognosis. 
Given the strong prognostic value of SALL4 es-
tablished in our retrospective study, we propose 
that the prognostic value of SALL4 should be 
further verified in prospective clinical trials.
The discovery of a role for SALL4 in hepato-
cellular carcinoma, its association with progno-
sis, and the antitumor effects of a newly identi-
fied peptide blocker targeting it have potential 
therapeutic significance. Testing for the pres-
ence of SALL4 at diagnosis may be helpful not 
only for determining the prognosis but also for 
identifying patients who are likely to have a re-
sponse to treatment. Given the expression of 
SALL4 in hepatocellular carcinoma cells but not 
in normal adult hepatocytes, treatment with 
SALL4 peptide may have less tissue toxicity, 
which is especially beneficial in patients with 
underlying cirrhosis whose baseline liver func-
tion is already compromised. Future studies will 
determine whether this peptide has synergistic 
potential with other molecular therapies, such as 
sorafenib, which act on parallel nonoverlapping 
pathways.
In conclusion, our study shows that the on-
cofetal protein SALL4 plays an important role in 
the extensive network of heterogeneous cellular 
pathways underlying hepatocarcinogenesis. A 
12–amino acid peptide can block the oncogenic 
role of SALL4 and hence has therapeutic poten-
tial in SALL4-positive hepatocellular carcinoma. 
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